Hexarelin (2MG)

Additional Info

Properties

• Chemical Formula: C47H58N12O6
• Molecular Weight: 887.05 g/mol
• Sequence: His-2-Me-D-Trp-Ala-Trp-D-Phe-Lys-NH2
• Total Amount: 2mg (1 vial)
• Shelf Life: 36 months

Shipping

• Available for USA and Canada. For international orders, in case of shipment seizure, contact us for a 50% discount on your subsequent purchase.

Disclaimer

The information provided does not substitute medical advice, diagnosis, or treatment. Consult your physician or qualified healthcare provider for medical concerns. Never delay seeking medical advice based on information read or seen here. We assume no responsibility or liability for the use of our research compounds and products. Please note they are exclusively sold for research purposes and are not intended for personal use.

Additional Label & Product Information:

Essential Caution:

These chemicals are solely intended for research or laboratory use and lack FDA approval for human consumption.

Usage Instructions:

Avoid skin and eye contact. If contact occurs, rinse thoroughly with water. Seek medical assistance if feeling unwell or in case of accidental ingestion. Store the lyophilized (freeze-dried) peptide at room temperature upon receipt to prevent peptide degradation due to frequent freeze-thaw cycles.

Product Disclaimer:

This product is not designed to diagnose, treat, cure, or prevent any disease. Administer only as specified by your specific research or laboratory protocol.

Resources

1. Ghigo et al. (1996): In October 1996, the European Journal of Endocrinology published a study on the short-term effects of intranasal or oral Hexarelin in aging adults. The research indicated that Hexarelin did not induce desensitization of growth hormone responsiveness in this demographic (PMID: 8921821).
2. Bresciani et al. (2019): The International Journal of Molecular Sciences, in September 2019, investigated the impact of growth hormone secretagogues on calcium signaling in muscle tissues. The study highlighted their role in regulating calcium signaling, providing insights into potential physiological effects (PMID: 31491959; PMCID: PMC6769538).
3. Mao et al. (2014): The Journal of Geriatric Cardiology reported in September 2014 on the cardiovascular effects of Hexarelin. The study elucidated Hexarelin’s impact on cardiovascular function, emphasizing implications for heart health (PMID: 25278975; PMCID: PMC4178518).
4. McDonald et al. (2018): Physiology Reports, in May 2018, investigated Hexarelin’s effects on myocardial function and cardiac fibrosis in a mouse model of acute myocardial infarction. Findings suggested that Hexarelin treatment preserved myocardial function and reduced cardiac fibrosis in this context (PMID: 29756411; PMCID: PMC5949285).
5. Mosa et al. (2015): Endocrine, in June 2015, explored the roles of ghrelin and Hexarelin in diabetes and diabetes-associated heart diseases. The study examined their implications in diabetic conditions, particularly concerning heart health (PMID: 25645463).
6. Mosa et al. (2017): Endocrinology, in October 2017, investigated Hexarelin’s effects on lipid metabolic abnormalities in nonobese insulin-resistant male MKR mice. The study suggested that Hexarelin improved lipid metabolism in this specific model (PMID: 28977588; PMCID: PMC5659698).
7. Imbimbo et al. (1994): European Journal of Clinical Pharmacology published a dose-response study in 1994 on Hexarelin’s growth hormone-releasing activity in humans. The research provided insights into the dose-dependent effects of Hexarelin on growth hormone release (PMID: 7957536).